DUBLIN, Nov. 14, 2016 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that Adriane M. Brownwill join its board of directors effective February 2017. Ms. Brown is currently President and Chief Operating Officer of Intellectual Ventures LLC, a private global invention company focused on providing access to valuable
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
"Adriane Brown is an accomplished executive with extensive experience leading global businesses in multiple industries. With nearly 30 years of management experience, she has operational know how and a proven track record of developing and growing technologies and products across a network of global R&D centers and manufacturing plants," said Brent Saunders, Chairman, Chief Executive Officer and President of Allergan plc. "Adriane's public board experience, understanding of the value of innovation and experience developing and protecting intellectual property complements the experiences of our current board."
Ms. Brown has served on the board of directors of Harman International Industries, Inc. since June 2013 where she is a member of the Compensation Committee and the Technology and Innovation Committee.
"I am pleased to join the board of Allergan as they deliver results around the world that serve their customers and patients," said Brown. "Their commitment to innovative and meaningful work with the goal of helping people live longer and healthier is commendable."
Prior to joining intellectual Ventures in 2010, Ms. Brown was Senior Vice President, Energy Strategy at Honeywell International. During the course of her eleven year career at Honeywell, Ms. Brown served in a number of leadership positions including, President and Chief Executive Officer, Honeywell Transportation Systems; Vice President and General Manager, Engine Systems & Accessories; and Vice President and General Manager, Aircraft Landing Systems.
Prior to joining Honeywell, Ms. Brown had a nearly 20 year career at Corning, Inc. Ms. Brown's last position at Corning was Vice President and General Manager, Environmental Products Division. This followed roles of increasing responsibility starting with her first position as a shift supervisor.
Ms. Brown received her Bachelor of Science in environmental health from Old Dominion University and a Masters of Science in management (Sloan Fellow) from Massachusetts Institute of Technology. She also received a Doctorate of Humane Letters from Old Dominion University.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
Allergan:Investors:Lisa DeFrancesco(862) 261-7152
Media:Mark Marmur(862) 261-7558
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/adriane-m-brown-to-join-allergan-plc-board-of-directors-300362031.html
SOURCE Allergan plc
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All